• Monthly
  • $25
  • $50
  • $100
  • $other
  • use PayPal


Is it time for our Spring fundraiser already? If you enjoy what we offer, and have the means, please consider donating. The sooner we reach our modest goal, the faster we can get back to business as (un)usual. Please, stay safe and we’ll see you down the road.

Death By Tweetstorm: a Win-Win for Trump

Photograph by Nathaniel St. Clair

For lack of respirators, patients with severe respiratory distress from COVID-19 will die as the epidemic unfolds. A drug to treat the disease is urgently needed. But the US press subjected news about hydroxychloroquine, a potential treatment, to an excess of caution in response to a Trump tweetstorm. Journalists and health care professionals alike were whipsawed by the president’s irresponsible ballyhooing of the drug amid deprecatory assertions of “anecdotal” evidence by Anthony Fauci at the CDC.

This fast-moving story started picking up steam with results from a small trial of hydroxychloroquine to treat COVID-19 out of Marseilles, France, by a well-known infectious disease specialist, Didier Raoult. It follows upon another small study from China, also promising. The drug has been used to treat immune-related disease for more than 60 years. It deserves the serious consideration it’s getting from the Europeans and Chinese.

The French trial included 36 patients, 16 of whom were controls who did not receive the drug. The 20 remaining patients, all with confirmed COVID-19 infection, were treated with hydroxychloroquine for 14 days. Some were asymptomatic, others had symptoms. Six of the patients also received an antibiotic, azithromycin.

The striking result was diminished viral load in the treated patients. As Raoult and colleagues put it in their as-yet unpublished paper, “70% of hydroxychloroquine-treated patients were virologicaly cured comparing with 12.5% in the control group.” Although the mechanism of action with this virus is not known, it’s been biochemically well-characterized; it’s not snake oil.

In that context, Trump’s endorsement, laced with ignorance, made things worse. In response came Anthony Fauci’s March 20 mischaracterization of the data as “anecdotal.” He was soon more concessional in his comments but Trump’s words met their mark. The next day the New York Times reported that the drug was “being prescribed right and left.”

Trump’s tweets sewed confusion and nixed hopes for a rational scenario. Concern about insufficient supply, unruly demand, and hysteria are well-placed. A rational approach would have been for the government to ensure provision for hydroxychloroquine to coincide as much as possible with the certain-to-come spike in severe cases. On global stage, this is already happening.  Drug makers are ramping up production. Novartis says it’s donating up to 130 million doses of the drug to the global pandemic.

As with any potential treatment, results from a couple of small trials warrant caution. In the case of hydroxychloroquine, the drug has been around since 1955. It has well-known adverse effects in some patients — those with heart disease, for example. But its safety profile would not be a problem for most.

It should be added that calls for huge trials ahead of approving this drug are misplaced. Based on their results, Raoult and colleagues have calculated that just 48 patients would be required to further test hydroxychloroquine, 24 to receive the drug and 24 controls. That’s a small number, but large enough.  Eighty years ago, penicillin required just about 5 patients for the decision to scale up manufacture.

The news out of Raoult’s laboratory is possibly nothing, possibly game-changing; It could have given patients, doctors, and especially hospital administrators much-needed mental room for organization and thoughtful emergency planning. The drug could have been an antidote to fear that “the sky is falling,” as Cornelia Griggs wrote in The Times (Op-Ed, March 19). Now, as far as it concerns panic, it’s too late.

Trump’s tweetstorm about hydroxychloroquine during a medical emergency of historic proportion will cost lives. But for Trump himself, there’s no downside. If the drug works, he will cover himself in glory. If it doesn’t — well, his friend Fauci told you so.

More articles by:

John Galbraith Simmons is author, in collaboration with Justin A. Zivin MD, PhD, of tPA for Stroke: The Story of a Controversial Drug (Oxford Univ Press, 2010).

Weekend Edition
May 29, 2020
Friday - Sunday
Nick Pemberton
White Supremacy is the Virus; Police are the Vector
T.J. Coles
What’s NATO Up to These Days? Provoking Russia, Draining Healthcare Budgets and Protecting Its Own from COVID
Benjamin Dangl
Bibles at the Barricades: How the Right Seized Power in Bolivia
Kevin Alexander Gray - Jeffrey St. Clair - JoAnn Wypijewski
There is No Peace: an Incitement to Justice
Jeffrey St. Clair
A Few Good Sadists
David Schultz
Trump isn’t the Pope and This Ain’t the Middle Ages
Joshua Frank
In Search of a Lost Socialism
Charles Pierson
Who are the “Wrong Hands” in Yemen?
Andrew Levine
Trump Is Unbeatable in the Race to the Bottom and So Is the GOP
Ramzy Baroud
Political Ambiguity or a Doomsday Weapon: Why Abbas Abandoned Oslo
Pam Martens - Russ Martens
A Growing Wave of Bankruptcies Threatens U.S. Recovery
Joseph Natoli
Conditions Close at Hand
N.D. Jayaprakash
No Lessons Learned From Bhopal: the Toxic Chemical Leak at LG Polymers India 
Ron Jacobs
The Odyssey of Elias Demetracopoulos
J.P. Linstroth
Arundhati Roy on Indian Migrant-Worker Oppression and India’s Fateful COVID Crisis
Melvin Goodman
Goodness Gracious, David Ignatius!!
Roger Harris
Blaming the COVID-19 Pandemic on Too Many Humans:  a Critique of Overpopulation Ideology
Sonali Kolhatkar
For America’s Wealthiest, the Pandemic is a Time to Profit
Prabir Purkayastha
U.S. Declares a Vaccine War on the World
David Rosen
Coronavirus and the Telecom Crisis
Paul Buhle
Why Does W.E.B. Du Bois Matter Today?
Mike Bader
The Only Way to Save Grizzlies: Connect Their Habitats
Dave Lindorff
Pandemic Crisis and Recession Can Spark a Fight for Real Change in the US
Nyla Ali Khan
The Sociopolitical and Historical Context That Shaped Kashmiri Women Like My Grandmother in the 1940s
Louis Proyect
Does Neo-Feudalism Define Our Current Epoch?
Ralph Nader
S. David Freeman: Seven Decades of Participating in Power for All of Us
Norman Solomon
Amy Klobuchar, Minneapolis Police and Her VP Quest
Maria Paez Victor
Venezuela in the 2020 Pandemic
Ron Mitchell
Defending Our Public Lands: One Man’s Legacy
Nomi Prins 
The Great Depression, Coronavirus Style: Crashes, Then and Now
Richard C. Gross
About That City on A Hill
Kathleen Wallace
An Oath for Hypocrites
Eve Ottenberg
Common Preservation or Extinction?
Graham Peebles
Air Pollution Mental Illness and Covid-19
Unearned Income for All
Evan Jones
The Machine Stops
Nicky Reid
Proudhon v. Facebook: A Mutualist Solution to Cyber Tyranny
Kollibri terre Sonnenblume
What is a “Native” Plant in a Changing World?
Shailly Gupta Barnes
Why are Our Leaders Still Putting Their Faith in the Rich?
John Kendall Hawkins
In Search of the Chosŏn People of Lost Korea
Nick Licata
How Hydroxychloroquine Could Help Trump…Politically
Jill Richardson
Tens of Millions of Are Out of Work, Why on Earth is Trump Trying to Cut Food Aid?
Susan Block
Incel Terrorism
Mitchel Cohen
Masks and COVID-19: an Open Letter to Robert Kennedy Jr and Children’s Health Defense
May 28, 2020
Melvin Goodman
Trump’s War on Arms Control and Disarmament